1. Home
  2. NOTE vs CTSO Comparison

NOTE vs CTSO Comparison

Compare NOTE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$1.90

Market Cap

39.9M

Sector

Technology

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.69

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTE
CTSO
Founded
2013
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
45.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NOTE
CTSO
Price
$1.90
$0.69
Analyst Decision
Strong Buy
Buy
Analyst Count
4
2
Target Price
$29.25
$5.38
AVG Volume (30 Days)
238.6K
124.8K
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$102,673,000.00
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
$0.55
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$1.83
$0.60
52 Week High
$24.36
$1.61

Technical Indicators

Market Signals
Indicator
NOTE
CTSO
Relative Strength Index (RSI) 27.09 41.67
Support Level $1.88 $0.70
Resistance Level $2.15 $0.76
Average True Range (ATR) 0.19 0.07
MACD 0.04 0.00
Stochastic Oscillator 10.88 32.52

Price Performance

Historical Comparison
NOTE
CTSO

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: